Management of chronic renal insufficiency in frail older patients who are unfit for renal replacement therapy

Reviews in Clinical Gerontology

Volumn 13, Issue 1, 2003, Pages 25-37

  Czapla, Krystyna ^a,b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; CAPSAICIN; CARBAMAZEPINE; CLONAZEPAM; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMOLLIENT AGENT; ERYTHROPOIETIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LEVODOPA; LOOP DIURETIC AGENT; MENTHOL; METOLAZONE; QUININE; RENIN; STATINE DERIVATIVE; THIAZIDE DIURETIC AGENT; VITAMIN D;

ACIDOSIS; AGED; ANEMIA; BLOOD GLUCOSE MONITORING; CHRONIC KIDNEY FAILURE; COMORBIDITY; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE COURSE; DYSPNEA; EDEMA; FLUID RETENTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPERTENSION; INSOMNIA; INSULIN RESISTANCE; IRON THERAPY; KIDNEY FAILURE; NATRIURESIS; NUTRITION; PALLIATIVE THERAPY; PATIENT REFERRAL; PRACTICE GUIDELINE; PROTEIN RESTRICTION; PRURITUS; RENAL OSTEODYSTROPHY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; TASTE DISORDER; UREMIA; VITAMIN DEFICIENCY; ZINC DEFICIENCY;

EID: 0742289015     PISSN: 09592598     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0959259803013133     Document Type: Review

References (89)

1. Reikes ST. Trends in end-stage renal disease. Epidemiology, morbidity, and mortality. Postgrad Med 2000; 108: 124-42.
2. Mirowsky J. Subjective life expectancy in the US: correspondence to actuarial estimates by age, sex and race. Soc Sci Med 1999; 49: 967-79.
3. Vaupel JW. The remarkable improvement in survival at older age. Phil Trans R Soc Lond Biol Si 1997; 352 (1363): 1799-804.
4. Renal Data System. USRDS 1995 annual data report. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Disease, 1995.
5. National Kidney Foundation. Dialysis Outcomes Quality Initiative: Clinical practice guidelines. Initiation of dialysis. Am J Kidney Dis 1997; 30 (suppl 2): S70-73.
6. The Renal Association. Treatment of adult patients with renal failure. R Coll Physicians 1997; (Nov): 1-113.
7. Parry RG, Crowe A, Stevens JM, Mason JC, Roderick P. Referral of elderly patients with severe renal failure: questionnaire survey of physicians. BMJ 1996; 313 (7055): 466.
8. Nyengaard JR, Bendtsen TF: Glomerular number and size in relation to age, kidney weight and body surface in normal man. Anat Rec 1992; 232: 194-201.
9. Kaplan C, Pasternack B, Shah H, Gallo H. Age-related incidence of sclerotic glomeruli in human kidneys. Am J Pathol 1975; 80: 227-34.
10. Thomas SE, Anderson S, Gordon KL, Oyama TT, Shankland SJ, Johnson RJ. Tubulointerstitial disease in aging: Evidence for underlying peritubular capillary damage, a potential role for renal ischemia. J Am Soc Nephrol 1998; 9: 231-42.
11. Phillips PA, Rolls BJ, Ledingham JJG et al. Reduced thirst after water deprivation in healthy elderly men. N Engl J Med 1984; 311: 753-59.
12. Porush JG, Faubert PF: Chronic renal failure. In: Porush JG, Faubert PF eds. Renal disease in the aged. London: Little, Brown & Co, 1991.
13. Kaysen GA, Myers BD. The aging kidney. Clin Geriatr Med 1985; 1: 207-22.
14. Cox JR, Shalaby WA. Potassium changes with age. Gerontology 1981; 27: 340-44.
15. Adler S, Lindeman RD, Yiengst MJ, Beard E, Shock NW. Effect of acute acid load on urinary acid excretion by the aging human kidney. J Clin Med 1968; 72: 278-89.
16. Walser M. Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis 1998; 32: 23-31.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3-41.
18. Rolin III HA, Hall PM. Evaluation of glomerular filtration rate and renal plasma flow. In Jacobson HR, Striker GE, Klahr S eds. Principles and practice of nephrology. St Louis: Mosby 1995: 8-13.
19. National Kidney Foundation-K/DOQI. Clinical practice guidelines for chronic renal disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (suppl 1): S1-266.
20. SelCuk NY, Odabas AR, Cetinkaya R, Tonbul HZ, San A. Frequency and outcome of patients with acute renal failure have more causes than one in etiology. Ren Fail 2000; 22: 459-64.
21. Baraldi A, Ballestri M, Rapana R et al. Acute renal failure of medical type in an elderly population. Nephrol Dial Transplant 1998; 13 (suppl 7): 25-29.
22. NIH consensus conference statement. Morbidity and mortality of renal dialysis. Ann Intern Med 1994; 121: 62-70
23. Lamping DL, Constantinovici N, Roderick P et al. Clinical outcome, quality of life, and costs in the North Thames Dialysis Study of the elderly people on dialysis: a prospective cohort study. Lancet 2000; 356 (9241): 1543-50.
24. Chandna SM, Schulz J, Lawrence C, Greenwood RN, Farrington K. Is there a rational for rationing chronic dialysis? A hospital-based cohort study of factors affecting survival and morbidity. BMJ 1999; 318 (7178): 217-23.
25. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int 1989; 35: 670-74.
26. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trails. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study. Ann Intern Med 1997; 127: 337-45.
27. 1999 World Health Organization - International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83.
28. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting enzyme inhibition in diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
29. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45.
30. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685-93.
31. Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol 1995; 26: 394-400.
32. Fliser D, Schroter M, Neubeck M, Ritz E. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994; 46: 482-88.
33. DeFronzo RA, Beckles AD. Glucose intolerance following chronic metabolic acidosis in man. Am J Physiol 1979; 236: E328-E334.
34. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
35. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321 (7258): 405-12.
36. Klahr S, Levey AS, Beck GJ et al. The effect of dietary protein restriction and blood pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877-84.
37. Pedrini MT, Levey AS, Lan J et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis. Ann Intern Med 1996; 124: 627-32.
38. Ikizler TA, Greene J, Wingard RL et al. Spontaneous dietary protein intake during progression of chronic renal failure. J Am Soc Nephrol 1995; 6: 1386-91.
39. Mahajan SK, Prasad AS, Lambujon J, Abbasi AA, Briggs WA, McDonald FD. Improvement of uremic hypogeusia by zinc: a double-blind study. Am J Clin Nutr 1980; 33: 1517-21.
40. Frohling PT, Schmicker R, Kokot F et al. Influence of phosphate restriction, keto-acids and vitamin D on the progression of chronic renal failure. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 561-66.
41. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2000; 28: 2486-97.
42. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. J Hypertens 1998; 16: 1407-14.
43. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veteran Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-18.
44. Voelker JR, Cartwright-Brown D, Anderson S et al. Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 1987; 32: 572-78.
45. Batlle DC, Salem M, Levin M et al. More on therapy for hyperkalaemia in renal insufficiency. N Engl J Med 1989; 320: 1496-97.
46. McCane, Widdowson. The composition of foods. In: Holland B, Welch AA, Unwin ID, Buff DH, Paul AA, Southgate DAT eds. Royal Society of Chemistry, fifth edition. Cambridge, 2000.
47. Mora Palma FJ, Ellis HA, Cook DB et al. Osteomalacia in patients with chronic renal failure before dialysis or transplantation. Q J Med 1983; 52: 332-48.
48. Reaich D, Channon SM, Scrimgeour CM, Goodship TH. Ammonium chloride-induced acidosis increases protein breakdown and amino acid oxidation in humans. Am J Physiol 1992; 263: E735-E739.
49. Papadoyannakis NJ, Stefanidis CJ, McGeown M. The effect of correction on metabolic acidosis on nitrogen and potassium balance of patients with chronic renal failure. Am J Clin Nutr 1984; 40: 623-27.
50. Reaich D, Graham KA, Channon SM et al. Insulin-mediated changes in PD and glucose uptake after correction of acidosis in humans with CRF. Am J Physiol 1995; 268: E121-E126.
51. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Relationship between hematocrit and renal function in men and women. Kidney Int 2001; 59: 725-31.
52. Benz RL, Pressman MR, Hovick ET, Peterson DD. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). Am J Kidney Dis 1999; 34: 1089-95.
53. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE Jr. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763-73.
54. Eckardt KU. Cardiovascular consequences of renal anaemia and erythropoietin therapy. Nephrol Dial Transplant 1999; 14: 1317-23.
55. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001; 16: 307-12.
56. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in non-diabetic patients. Nephron 1997; 77: 176-85.
57. Working party for European best practice guidelines for the management of anaemia in patients with chronic renal failure. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 (suppl 2): 61-65.
58. NKF-DOQI Work Group: NKF-DOQI clinical practice guidelines for the treatment of anaemia of chronic renal failure. Am J Kidney Dis 1997; 30 (suppl 3): S192-240.
59. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 2000; 16: 967-74.
60. Mittman N, Sreedhara R, Mushnick R et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. 5: Am J Kidney Dis 1997; 30: 912-22.
61. Eschbach JW. Current concepts of anaemia management in chronic renal failure: Impact of NKF-DOQI. Semin Nephrol 2000; 20: 320-29.
62. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in haemodialyis patients. Am J Kidney Dis 1997; 29: 565-68.
63. Argilés A, Mourand G, Lorho R et al. Medical treatment of severe hyperparathyroidism and its influence on anaemia in end-stage renal failure. Nephrol Dial Transplant 1994; 9: 1809-12.
64. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206-10.
65. Plata R, Cornejo A, Arratia C et al. for the Commision on Global Advancement of Nephrology (COMGAN), Research Subcommittee of the International Society of Nephrology. Angiotensin-converting-enzyme inhibition therapy in altitude polycythemia: a prospective randomised trial. Lancet 2002; 359 (9307): 663-66.
66. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-75.
67. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 19: 303-17.
68. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993; 328: 171-75.
69. Chou FF, Lee CH, Chen JB. General weakness as an indication for parathyroid surgery in patients with secondary hyperparathyroidism. Arch Surg 1999; 134: 1108-11.
70. Sato S, Ohta M, Kawaguchi Y et al. Effects of parathyroidectomy on left ventricular mass in patients with hyperparathyroidism. Miner Electrolyte Metab 1995; 21: 67-71.
71. Ramsdell R. Renagel. A new and different phosphate binder. ANNA J 1999; 26: 346-47.
72. Hamdy NA, Kanis JA, Beneton MN et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310 (6976): 358-63.
73. Schõmig M, Ritz E. Use of vitamin D metabolites. Nephrol Dial Transplant 2000; 15 (suppl 5): 18-24.
74. Stein MS, Scherer SC, Walton SL et al. Risk factors for secondary hyperparathyroidism in a nursing home population. Clin Endocrinol 1996; 44: 375-83.
75. Chapuy MC, Preziosi P, Maamer M et al. Prevalence of Vitamin D insufficiency in an adult normal population. Osteoporos Int 1997; 7: 439-43.
76. Lips P, Hackeng WH, Jongen MJ, van Ginkel FC, Netelenbos JC. Seasonal variation in serum concentrations of parathyroid hormone in elderly people. J Clin Endocrinol Metab 1983; 57: 204-06.
77. Freaney R, McBrinn Y, McKenna MJ. Secondary hyperparathyroidism in elderly people: combined effect of renal insufficiency and vitamin D deficiency. Am J Clin Nutr 1993; 58: 187-91.
78. Fournier A, Moriniere P, Sebert JL et al. Calcium carbonate, an aluminium-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia. Kidney Int 1986; 18 (suppl): S114-S119.
79. Ritz E, Kûster S, Schmidt-Gayk H et al. Low dose calcitriol prevents the rise in 1,84-iPTH without effecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant 1995; 10: 2228-34.
80. Matsui C, Ida M, Hamada M, Morohashi M, Hasegawa M. Effects of azelastin on pruritus and plasma histamine levels in hemo-dialysis patients. Int J Dermatol 1994; 33: 868-71.
81. Reco PJ, Ende J. Pruritus: a practical approach. J Gen Intern Med 1992; 7: 340-49.
82. Robertson KE, Mueller BA. Uremic pruritus. Am J Health Syst Pharm 196; 53: 2159-70.
83. Wadhawa NK, Aktar S: Sleep disorders in dialysis patients. Sem Dialysis 1998; 11: 287-97.
84. Kimmel PL, Gavin C, Miller G, Mendelson WB, Wernli I, Neugarten J. Disordered sleep and non-compliance in a patient with end-stage renal disease. Adv Ren Replacement Ther 1997; 4: 55-67.
85. Auckley DH, Schmidt-Nowara W, Brown LK. Reversal of sleep apnea hypopnea syndrome in end-stage renal disease after kidney transplantation. Am J Kidney Dis 1999; 34: 739-44.
86. Winkelman JW, Chertow GM, Lazarus JM. Restless leg syndrome in end-stage renal disease. Am J Kidney Dis 1996; 28: 372-78.
87. Read DJ, Feest TG, Nassim MA. Clonazepam: effective treatment for restless legs syndrome in uraemia. BMJ 1981; 283 (6296): 885-86.
88. Trenkwalder C, Stiasny K, Pollmacher T et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind randomized crossover trial. Sleep 1995; 18: 681-89.
89. Ausserwinkler M, Schmidt P. Successful clonidine treatment of restless leg syndrome in chronic kidney insufficiency. Schweiz Med Wochenschr 1989; 11: 184-86.